Literature DB >> 28664099

Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery.

Eunji Shin1, Kyung Soo Ko1, Byoung Doo Rhee1, Jin Han1, Nari Kim1.   

Abstract

The aim of this review was to understand the effects of β-adrenergic stimulation on oxidative stress, structural remodeling, and functional alterations in the heart and cerebral artery. Diverse stimuli activate the sympathetic nervous system, leading to increased levels of catecholamines. Long-term overstimulation of the β-adrenergic receptor (βAR) in response to catecholamines causes cardiovascular diseases, including cardiac hypertrophy, stroke, coronary artery disease, and heart failure. Although catecholamines have identical sites of action in the heart and cerebral artery, the structural and functional modifications differentially activate intracellular signaling cascades. βAR-stimulation can increase oxidative stress in the heart and cerebral artery, but has also been shown to induce different cytoskeletal and functional modifications by modulating various components of the βAR signal transduction pathways. Stimulation of βAR leads to cardiac dysfunction due to an overload of intracellular Ca2+ in cardiomyocytes. However, this stimulation induces vascular dysfunction through disruption of actin cytoskeleton in vascular smooth muscle cells. Many studies have shown that excessive concentrations of catecholamines during stressful conditions can produce coronary spasms or arrhythmias by inducing Ca2+-handling abnormalities and impairing energy production in mitochondria, In this article, we highlight the different fates caused by excessive oxidative stress and disruptions in the cytoskeletal proteome network in the heart and the cerebral artery in responsed to prolonged βAR-stimulation.

Entities:  

Keywords:  catecholamine; cerebral artery; heart; β-adrenergic stimulation

Year:  2014        PMID: 28664099      PMCID: PMC5481746          DOI: 10.1016/j.imr.2014.10.002

Source DB:  PubMed          Journal:  Integr Med Res        ISSN: 2213-4220


Introduction

Chronic increased sympathetic activation occurs in many situations, including obesity, sleep apnea, mental stress, and hypertension, promoting the development of cardiovascular diseases through sustained stimulation of adrenergic receptors.1, 2, 3, 4 These fatal cardiac events include cardiac hypertrophy, heart failure, and sudden cardiac death.5, 6, 7, 8, 9 Elevated levels of catecholamines stimulate the α-adrenergic receptor and β-adrenergic receptor (βAR); however, most of the adverse cardiac effects associated with increased sympathetic tone on the heart have been believed to be caused mostly by stimulation of βAR in the heart. In fact, βAR blockade consistently improves cardiac function and survival in patients with heart failure.10, 11 By contrast, α-adrenergic receptor blockades is an effective antihypertensive approach, but may actually increase the risk of cardiovascular events, as shown in patients taking doxazosin in the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) trial. Use of the βAR blocker metoprolol during the perioperative period in patients with non-cardiac diseases was associated with an increased the risk of strokes and death. These studies suggest that sympatholytic agents are unlikely to be accepted as a common regimen for the treatment of both the heart and the vasculature simultaneously. Based on these findings, overstimulation of βAR appears to have different effects on the heart and cerebral artery. Therefore, the focus of this review is to compare cardiac and vascular, effects of beta AR stimulation and effects on related signal transduction processes.

Effect of prolonged βAR stimulation on the heart

Long-term βAR activation by various stressors induces serious myocardial damages, including cardiac hypertrophy, necrosis/apoptosis, and fibrosis.7, 9, 14, 15, 16 Cardiac hypertrophy is an independent cause of heart failure and major cause of morbidity and mortality throughout the world; thus, research and clinical interventions for cardiac hypertrophy have been extensively studied.17, 18, 19 Once cardiac hypertrophy develops, it progresses to heart failure. The underlying mechanisms associated with βAR overstimulation have been studied in vivo in heart tissue using isoproterenol (ISO)-treated models and in vitro in cultured cardiomyocytes. This βAR overstimulation represents an important hallmark of pathologic cardiac hypertrophy.15, 20, 21, 22, 23, 24 ISO treatment increases oxidative stress, protein synthesis, proto-oncogene expression, and stimulation of mitogen-activated protein kinases. These events are caused by altered of electrical and mechanical capabilities that induce three modes of cell death: necrosis, apoptosis, and autophagy (see Table 1).
Table 1

Gene/protein expression profiles in heart and cerebral artery by prolonged βAR stimulation

Identification and functional categoryHeart
Cerebral artery
ref.
increasedecreaseincreasedecrease
Apoptosis/necrosis
Bcl2l1Bcl-2-like-protein 1 (Bcl-XL)54
Bcl2l11Bcl-2-like protein 11+54
BmfBcl-2 modifying factor+54
Bak1Bcl-2 antagonist54
BaxBcl-2-associated X protein54
Pmaip1Phorbol-12-myristate-13-acetate-induced protein 1+54
SfnStratafin54
Tp53Tumor protein 53 (p53)54
Apaf1Apoptotic protease activating factor 1+54
Casp1Caspase-154
Casp2Caspase-2 (initiator)54
Casp3Caspase-3 (effector)+54
Casp7Caspase-7 (effector)54
Casp9Caspase-9 (initiator)+54
Tnfrsf1aTumor necrosis factor receptor superfamily 1A54
Tnfsf10Tumor necrosis factor (ligand) superfamily, 10+54
FasTumor necrosis factor receptor superfamily 6+54
Stress/energy
Abcb4ATP-binding cassette, subfamily B (MDR/TAP) 1A54
Abcc3ATP-binding cassette protein C354
AhrAryl-hydrocarbon receptor+54
Aktv-akt murine thymoma viral oncogene homolog 1+54
ALDH1A1Aldehyde dehydrogenase, family 1 member A1+35
ALDH2Aldehyde dehydrogenase, mitochondrial precursor+35
ANX6Annexin VI isoform 1+35
ANXA1Annexin A1 (annexin I)+35
ARHADP-ribosylhydrolase+55
Arnt2Aryl-hydrocarbon receptor nuclear translocator 254
ATP5bATP synthase subunit β, mitochondrial precursor+55
Bcat1Branched chain amino acid transaminase 1+54
CCT2Chaperonin containing TCP1, subunit 2 (beta)+35
DPYSL2Dihydropytimidinase-like2+35
EARHEcto ADP-ribosylhydrolase precursor+55
EARHEcto ADP-ribosylhydrolase precursor+55
EF1GElongation factor 1-gamma+35
GDI2GDP dissociation inhibitor 2+35
GLUD1Glutamate dehydrogenase+35
GSTM5Glutathione-S-transferase, mu5+35
Hif1anHypoxia-inducible factor 1-alpha inhibitor54
Hif3aHypoxia-inducible factor 3-alpha+54
HspHeart shock protein 75 kDa55
Hspa1LHeat shock 70 kDa, protein 1-like54
Hspb7Heat shock 27 kDa, cardiovascular+54
HspA2Heat shock 70 kDa, protein 2+54
HspA5Heat shock 70 kDa, protein 554
HspA8Heat shock 70 kDa, protein 8 (Hsp73)54
HSPA9Heat shock protein 9A, mortalin+35
IDH1Isocitrate dehydrogenase 1 (NADP+)+35
LamcIsoform C of lamin-A/C55
NDUFS1NADH dehydrogenase (ubiquinone) Fe–S protein 1+35
NDUFS8NADH dehydrogenase (ubiquinone) Fe–S protein 8+35
Nos2Nitric oxide synthase, inducible54
Nr1h4Nuclear receptor subfamily 1, group H, member 454
OTUB1Ubiquitin thioesterase protein OTUB1+55
PDIA3Protein disulfide isomerase family A, member3+35
PEA15Isoform 1 of astrocytic phosphoprotein PEA-15+55
PparγPeroxisome proliferator-activated receptor gamma54
PparαPPAR alpha54
PPIasePeptidyl-prolyl cis–trans isomerase E55
RALDH2Aldehyde dehydrogenase 1A2 isoform 1+35
RanGAPRan-specific GTPase-activating protein+55
RCN3Reticulocalbin-3 precursor55
STIP1Stress-induced phosphoprotein 1+35
Ucp3Mitochondrial uncoupling protein 354
VEGFAVascular endothelial growth factor A+54
14-3-3 β/αIsoform short 14-3-3 protein β/α55
Inflammation
C3Complement C354
C9Complement C9+54
Defb1Beta-defensin 1+54
EHD1EH-domain containing 1, isoform CRA_a+35
Fkbp1FK506-binding protein 155
Ifna1Interferon, alpha 154
Il-1αInterleukin-1 alpha+54
Il-1βInterleukin-1 beta+54
IL6Interleukin-6+54
MSNMoesin+35
PSME1Proteasome activator complex subunit 155
TNFαTumor necrosis factor alpha54
TGFb2Transforming growth factor b254
Remodeling/fibrosis
ACTA20Actin, alpha 2, smooth muscle+35
ACTR1AActin-related protein 1+35
ACTR2Actin-related protein 2 homolog+35
ACTC1Alpha-actin+35
ALBAlbumin+35
BMMBone marrow macrophage cDNA55
CAPZBCapping protein (actin filament) muscle Z-line+35
Ccl7Chemokine ligand 7+54
COL6A2Alpha-2-collagen type VI+35
CORO1BCoronin-1B+35
CtgfConnective tissue growth factor54
Fhl1Four half Lim domain54
GRIPAP1GRIP1-associated protein 1+35
Il4Interleukin-454
Pdlim1PDZ and LIM domain protein 1+55
Reg3bRegenerating islet-derived 3 beta54
Reg3gRegenerating islet-derived 3 gamma54
SEPT8Septin+35
Spp1Osteopontin54
Timp1Tissue inhibitor metalloproteinase 154
VIMVimentin+35
WDR1WD repeat-containing protein 1 isoform 8+35
Gene/protein expression profiles in heart and cerebral artery by prolonged βAR stimulation Furthermore, ISO treatment alters related signal transduction pathways. In the normal heart, βAR activation stimulates adenylyl cyclase activity via Gs protein-coupled receptors, which leads to the formation of cAMP. Increased cAMP elevates intracellular concentrations of Ca2+, which activates protein kinase A (PKA)-mediated phosphorylation of different Ca2+-handling proteins, producing positive inotropic effects in the heart. However, long-term ISO stimulation results in desensitization of the PKA-dependent receptor after previous phosphorylation, thus attenuating βAR-mediated response.15, 25, 26 Tse et al showed that cardiac hypertrophy develops in rats treated chronically with ISO stimulation; further, these rats showed decreased magnitude and sensitivity of contractility in vitro in response to ISO stimulation. These effects were, related to biochemical alterations, including decreased numbers of βARs, decreased sensitivity and magnitude of adenylate cyclase activity, and decreased cAMP formation. We also clearly showed that PKA activity, but not protein kinase C (PKC) activity, in the rabbit heart decreased gradually with time after prolonged βAR stimulation. In addition to the study of Tse et al, underlying mechanisms of βAR desensitization to an agonist may be associated with an increased βAR kinase activity. This possibility is supported by the finding that βAR stimulation can significantly increase the expression of βAR kinase 1, whereas βAR blockade decreases the expression.

Effect of prolonged βAR stimulation on the vasculature

Despite massive studies on the effects of ISO treatment on the heart, few studies have been performed to evaluate its effects on the vasculature. Pathological cardiac hypertrophy caused by overstimulation of βAR is a potent, independent predictor of cerebrovascular events such as stroke.29, 30 In diverse vessels, such as the femoral, pulmonary, and carotid arteries, acute stimulation of βAR induces vasodilation. Long-term stimulation of βAR in arteries, however, can induce alterations in vascular contractility. Previously, we demonstrated that prolonged ISO treatment in rabbits leads to abnormalities in the coronary arterial functions through alterations in the Ca2+-activated K+ and inward- rectifier K+ channels in smooth muscle cells. This implies a novel mechanism for vascular dysfunction during cardiac hypertrophy.14, 32 With regard to the rat aorta, Davel et al demonstrated that prolonged ISO stimulation induced endothelial dysfunction and increased vasoconstriction by phenylephrine, an α-adrenergic receptor agonist, due to endothelial dysfunction. They suggested that ISO treatment enhanced the vasoconstrictor response and increased oxidative stress via Endothelial Nitric Oxide Synthase (eNOS) uncoupling, through the β2AR/Giα signaling pathway. Interestingly, we found that βAR stimulation decreased transient Ca2+ efflux and attenuated contraction in response to angiotensin II in the rabbit cerebral artery. Possible mechanisms of abnormal response to vasoactivity in different arteries may be due to factors other than biochemical alterations, as shown in the heart. These include the possibility that vascular tissues are vulnerable to oxidative stress, which may disrupt the cytoskeleton further.

Differential modulation of the proteome in the heart and cerebral artery during βAR stimulation

To help improve interventions for managing cerebrovascular events during cardiac hypertrophy, here we focus on differences between cardiac and vascular signaling during prolonged βAR stimulation. Inducible proto-oncogenes encode nuclear transcription factors and activate promoters of many target genes playing a that have roles in cellular functions, adaptive processes, or cell death.36, 37, 38 Prolonged βAR stimulation increases the phosphorylation of Extracellular signal-Regulated Kinase (ERK) increasing expression of c-fos and c-myc in the cerebral arteries, whereas only c-fos expression corresponds to the increased phosphorylation of ERK in the heart. Therefore, post-translational modulation appears to progress via different mechanisms in the heart and the cerebral artery. Although cardiac hypertrophy is not known to be a prerequisite for altered expression of proto-oncogenes in vivo, βAR stimulates Gi-dependent PI3 kinase (PI3K) activity and cell growth. In human erythroid progenitors cells, PKCα and PI3Kγ pathways are parallel and converge to activate the c-fos and c-myc genes. In addition, decreased signaling of the Ras/Raf/MEK/ERK cascade in the cerebral artery during cardiac hypertrophy can interrupt the actin cytoskeletal network, because Ras/Raf/MEK/ERK is essential for actin-base cytoskeletal organization.42, 43 In contrast, Ras and Raf are activated in the heart during cardiac hypertrophy, and may roles in proliferation and transformation. Decreased PKA activity may possibly contribute indirectly to decreased expressions of the Ras/Raf/MEK/ERK signaling in the cerebral artery, because PKA activity is well known to innately correspond with Ras/Raf activation. However, recent findings also demonstrated that PKA activation does not contribute to Ras/Raf activation.44, 46 Thus we suggested that the underlying mechanism of vascular dysfunction resulting from the decreased expression levels of RhoA and ROCK1 proteins after βAR stimulation. RhoA and ROCK1 are involved in actin-cytoskeletal organization and phosphorylation of myosin light chain producing smooth muscle contraction. The contractility of vascular smooth muscle cells is widely regulated by the cytoskeletal proteome network. Our previous study clearly shows that βAR stimulation disrupts the actin cytoskeletal proteome network through downregulation of RhoA/ROCK1 proteins attenuating angiotensin II-induced contraction in the cerebral artery. Cardiac or cerebral remodeling by βAR stimulation may involve changes in cellular energy. However, there are a few studies of proteome analysis of βAR stimulated pathways in the heart and the cerebral artery; these studies, revealed similarities in the main response, including: apoptosis/necrosis, stress/energy, inflammation, and remodeling/fibrosis (also see Table 1). In the heart, a greater number of genes are altered in the category of energy or remodeling, whereas, a greater number of genes involved in cytoskeletal organization are altered in the cerebral artery. Regarding oxidative stress, expression levels of several cytoprotective chaperones and protein maturation elements are significantly decreased in both the heart and the cerebral artery. Excessive levels of reactive oxygen species (ROS) results in oxidative stress, because the balance between production of ROS and activation of the antioxidant system is essential for controlling homeostasis. Sustained high levels of circulating catecholamines induced by stress can result in cardiotoxicity due to the production of oxygen free radicals. This is supported by several recent findings demonstrating that βAR stimulation increase ROS production in the HEK293 cells, rat cardiac myocytes, and the rat aorta.50, 51, 52 Increased oxidative stress can also lead to DNA damage.35, 53 Interestingly, in either the heart or the cerebral artery, decreased levels of cytoprotective proteins, including heat shock protein 70/90 and stress-induced-phosphoprotein 1, are more likely due to cause deleterious effects35, 54, 55 -rather than increased ROS production. Heat shock proteins are crucial to cellular defense and mitochondrial protection against oxidative stress; these are ubiquitous and highly conserved chaperones are associated with myocardial protection. Oxidative stress activates several kinase signaling pathways, such as PKC, Mitogen-activated protein kinases (MAPK), and PI3K. In particular, the Bcl-2 like protein 1 and Bak1, which are associated with mitochondria, are significantly altered in the heart. These proteins induce apoptosis by regulating metabolite diffusion across the outer mitochondrial membrane. Apoptosis during cardiac hypertrophy caused by βAR stimulation is of particular interest, as recent literature indicates that deterioration of the hypertrophied heart is linked to progressive loss of cardiomyocytes. Other groups have also shown that inhibition of apoptosis is accompanied by attenuation of heart failure and cardiac hypertrophy, along with increased cardiomyocyte apoptosis prior to the development of significant heart failure.60, 61 Taken together, modulation of apoptosis during cardiac hypertrophy as a preventive for heart failure or stroke may lead to viable therapeutic modalities in the near future.

Conclusion

Epinephrine and norepinephrine injections stimulate αAR and βAR can cause cardiac cell damage to a qualitatively similar extent. In contrast, ISO injection stimulates only βAR can impair the myocardium more severely. Therefore, most of the studies have focused on understanding βAR-mediated signal transduction mechanisms and finding targets to prevent βAR-mediated cardiac remodeling. More recently, βAR overstimulation of vascular structural and function has shown differential effects compared to that of the heart. Therefore, cerebrovascular remodeling and dysfunction reviewed in this study may give a new insight into understanding cerebral damage after βAR overstimulation, during long-term stress and therapeutic intervention of βAR overstimulation induced cardiovascular events.

Conflicts of interest

There are no conflicts of interest.
  61 in total

1.  Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.

Authors:  P Lechat; M Packer; S Chalon; M Cucherat; T Arab; J P Boissel
Journal:  Circulation       Date:  1998-09-22       Impact factor: 29.690

Review 2.  The role of inducible transcription factors in apoptotic nerve cell death.

Authors:  M Dragunow; K Preston
Journal:  Brain Res Brain Res Rev       Date:  1995-07

3.  White-coat hypertension and autonomic nervous system dysregulation.

Authors:  Serina A Neumann; J Richard Jennings; Matthew F Muldoon; Stephen B Manuck
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

4.  The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase.

Authors:  A Chesley; M S Lundberg; T Asai; R P Xiao; S Ohtani; E G Lakatta; M T Crow
Journal:  Circ Res       Date:  2000-12-08       Impact factor: 17.367

5.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.

Authors:  K A Krown; M T Page; C Nguyen; D Zechner; V Gutierrez; K L Comstock; C C Glembotski; P J Quintana; R A Sabbadini
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

6.  Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.

Authors:  Mevlut Sait Keles; Yasin Bayir; Halis Suleyman; Zekai Halici
Journal:  Mol Cell Biochem       Date:  2009-03-19       Impact factor: 3.396

7.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade.

Authors:  G Iaccarino; E D Tomhave; R J Lefkowitz; W J Koch
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

8.  Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta.

Authors:  Ana Paula C Davel; Livia E Fukuda; Larissa Lima De Sá; Carolina D Munhoz; Cristoforo Scavone; David Sanz-Rosa; Victoria Cachofeiro; Vicente Lahera; Luciana V Rossoni
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-16       Impact factor: 4.733

9.  Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice.

Authors:  Mounir Errami; Cristi L Galindo; Amina T Tassa; John M Dimaio; Joseph A Hill; Harold R Garner
Journal:  J Pharmacol Exp Ther       Date:  2007-12-18       Impact factor: 4.030

10.  Changes in the Ca2+-activated K+ channels of the coronary artery during left ventricular hypertrophy.

Authors:  Nari Kim; Joonyong Chung; Euiyong Kim; Jin Han
Journal:  Circ Res       Date:  2003-08-07       Impact factor: 17.367

View more
  6 in total

Review 1.  β-Adrenergic receptor, an essential target in cardiovascular diseases.

Authors:  Daniel Chikere Ali; Muhammad Naveed; Andrew Gordon; Fatima Majeed; Muhammad Saeed; Michael I Ogbuke; Muhammad Atif; Hafiz Muhammad Zubair; Li Changxing
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

2.  Pin1 facilitates isoproterenol‑induced cardiac fibrosis and collagen deposition by promoting oxidative stress and activating the MEK1/2‑ERK1/2 signal transduction pathway in rats.

Authors:  Xian Wu; Mingjiang Li; Su-Qin Chen; Sha Li; Furong Guo
Journal:  Int J Mol Med       Date:  2017-12-29       Impact factor: 4.101

3.  Binge Alcohol Exposure in Adolescence Impairs Normal Heart Growth.

Authors:  Lizhuo Ai; Edith Perez; AnnaDorothea Asimes; Theerachat Kampaengsri; Maxime Heroux; Andrei Zlobin; Mark A Hiske; Charles S Chung; Toni R Pak; Jonathan A Kirk
Journal:  J Am Heart Assoc       Date:  2020-04-22       Impact factor: 5.501

4.  Associations between triglyceride-glucose index and different hypertension subtypes: A population-based study in China.

Authors:  Qian Cai; Cathleen Y Xing; Jiang Zhu; Ying Wang; Fanghong Lu; Jie Peng
Journal:  Front Cardiovasc Med       Date:  2022-08-11

5.  Isosteviol prevents the development of isoprenaline‑induced myocardial hypertrophy.

Authors:  Yaoxu Chen; Huimin Beng; Hao Su; Fuping Han; Zhuo Fan; Nanying Lv; Aleksandar Jovanović; Wen Tan
Journal:  Int J Mol Med       Date:  2019-09-17       Impact factor: 4.101

6.  Increased β-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling.

Authors:  Barbara Moser; Florian Poetsch; Misael Estepa; Trang T D Luong; Burkert Pieske; Florian Lang; Ioana Alesutan; Jakob Voelkl
Journal:  Pflugers Arch       Date:  2021-09-26       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.